Market Overview:
The global Parkinson's disease market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth can be attributed to the increasing prevalence of Parkinson's disease, rising awareness about the available treatment options, and growing demand for better treatment outcomes. The global Parkinson's disease market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into carbidopa/levodopa and dopamine receptor agonists. Dopamine receptor agonists are further sub-segmented into non-ergot and ergot derivatives. On the basis of application, hospitals accounted for majority share in 2017 owing to increasing number of patients with advanced stages of Parkinson's disease who require hospitalization for management and care.
Product Definition:
Parkinson's disease is a progressive neurological disorder that affects movement. It develops gradually, often starting with a slight tremor in one hand. As the disease progresses, people may have difficulty walking, talking, and completing other simple tasks. There is no cure for Parkinson's disease, but medications can help relieve symptoms.
Carbidopa/Levodopa:
Carbidopa/Levodopa (Sinemet) is a drug developed to treat the symptoms of Parkinson's disease. It is also used as an off-label anti-epileptic and anti-seizure medication. Carbidopa/Levodopa works by increasing the amount of dopamine in the brain, which reduces the severity of certain motor symptoms such as stiffness, walking problems & balance issues associated with Parkinson’s disease.
Dopamine Receptor Agonists:
Dopamine receptor agonists is a class of drug that modifies the biological response to dopamine. Dopamine is a chemical messenger that controls many functions such as movement, memory, and emotions. Parkinson’s disease or more commonly known as PD is caused when there are insufficient levels of dopamine in the brain. The main symptom associated with PD is walking problems.
Application Insights:
The application segment is segregated into hospitals and clinics. Clinics held the largest share of more than 60% in 2017. The segment will expand further at a steady CAGR owing to increasing awareness about PD treatment, growing patient base and rising number of clinics in emerging economies such as India, China, Thailand etc. Hospitalization was the second-largest application segment with a share of nearly 40% in 2017 due to higher prevalence among older population and travel restrictions for people suffering from PD caused by infection or surgery related complications.
Increasing awareness among people regarding timely treatment is expected to drive the market growth over the forecast period owing to increasing cases diagnosed with PD globally every year since 1980s when it was firstly recognized as a disease entity by international organizations such as ULCA (Uruguay) & ILAE (Geneva).
Regional Analysis:
North America dominated the overall market in terms of revenue share in 2017. The region is expected to maintain its dominance over the forecast period as well owing to factors such as favorable government initiatives, high disposable income, and availability of effective treatment methods. Moreover, increasing awareness about neurodegenerative disorders among people is also contributing toward regional growth.
Asia Pacific Parkinson's disease (APD) market is anticipated to grow at a lucrative rate during the forecast period due to factors such as rising healthcare expenditure and growing patient awareness levels regarding available treatment options for PD. In addition, increasing prevalence of diabetes in this region will boost APD demand further because it increases risk for development of neurodegenerative disorders like Parkinson’s disease (PD). Rising disposable income will also contribute toward regional growth over the next few years.
Growth Factors:
- Increasing awareness about Parkinson's disease and its symptoms.
- Growing population of elderly people, who are more susceptible to Parkinson's disease.
- Rising prevalence of neurodegenerative diseases worldwide.
- increasing research and development expenditure for the treatment of Parkinson's disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Parkinson's Disease Market Research Report
By Type
Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors
By Application
Hospitals, Clinics
By Companies
Teva, Novartis, GSK, AbbVie, Merck, Boehringer Ingelheim, Amneal + Impax, Lundbeck, Sun Pharma, Wockhardt, UCB, Bausch Health, Acadia
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
158
Number of Tables & Figures
111
Customization Available
Yes, the report can be customized as per your need.
Global Parkinson's Disease Market Report Segments:
The global Parkinson's Disease market is segmented on the basis of:
Types
Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Novartis
- GSK
- AbbVie
- Merck
- Boehringer Ingelheim
- Amneal + Impax
- Lundbeck
- Sun Pharma
- Wockhardt
- UCB
- Bausch Health
- Acadia
Highlights of The Parkinson's Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Carbidopa/Levodopa
- Dopamine Receptor Agonists
- MAO-Inhibitors
- By Application:
- Hospitals
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Parkinson's Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Parkinson's disease is a neurodegenerative disorder that affects the central nervous system. It results from the death of cells in the brain that produce dopamine, a chemical important for movement and coordination. Symptoms typically develop slowly over time, and may include difficulty walking, speaking, swallowing, and controlling body movements. Parkinson's disease can be fatal if not treated properly.
Some of the key players operating in the parkinson's disease market are Teva, Novartis, GSK, AbbVie, Merck, Boehringer Ingelheim, Amneal + Impax, Lundbeck, Sun Pharma, Wockhardt, UCB, Bausch Health, Acadia.
The parkinson's disease market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Parkinson's Disease Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Parkinson's Disease Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Parkinson's Disease Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Parkinson's Disease Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Parkinson's Disease Market Size & Forecast, 2018-2028
4.5.1 Parkinson's Disease Market Size and Y-o-Y Growth
4.5.2 Parkinson's Disease Market Absolute $ Opportunity
Chapter 5 Global Parkinson's Disease Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Parkinson's Disease Market Size Forecast by Type
5.2.1 Carbidopa/Levodopa
5.2.2 Dopamine Receptor Agonists
5.2.3 MAO-Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Parkinson's Disease Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Parkinson's Disease Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Parkinson's Disease Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Parkinson's Disease Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Parkinson's Disease Analysis and Forecast
9.1 Introduction
9.2 North America Parkinson's Disease Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Parkinson's Disease Market Size Forecast by Type
9.6.1 Carbidopa/Levodopa
9.6.2 Dopamine Receptor Agonists
9.6.3 MAO-Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Parkinson's Disease Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Parkinson's Disease Analysis and Forecast
10.1 Introduction
10.2 Europe Parkinson's Disease Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Parkinson's Disease Market Size Forecast by Type
10.6.1 Carbidopa/Levodopa
10.6.2 Dopamine Receptor Agonists
10.6.3 MAO-Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Parkinson's Disease Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Parkinson's Disease Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Parkinson's Disease Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Parkinson's Disease Market Size Forecast by Type
11.6.1 Carbidopa/Levodopa
11.6.2 Dopamine Receptor Agonists
11.6.3 MAO-Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Parkinson's Disease Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Parkinson's Disease Analysis and Forecast
12.1 Introduction
12.2 Latin America Parkinson's Disease Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Parkinson's Disease Market Size Forecast by Type
12.6.1 Carbidopa/Levodopa
12.6.2 Dopamine Receptor Agonists
12.6.3 MAO-Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Parkinson's Disease Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Parkinson's Disease Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Parkinson's Disease Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Parkinson's Disease Market Size Forecast by Type
13.6.1 Carbidopa/Levodopa
13.6.2 Dopamine Receptor Agonists
13.6.3 MAO-Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Parkinson's Disease Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Parkinson's Disease Market: Competitive Dashboard
14.2 Global Parkinson's Disease Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Novartis
14.3.3 GSK
14.3.4 AbbVie
14.3.5 Merck
14.3.6 Boehringer Ingelheim
14.3.7 Amneal + Impax
14.3.8 Lundbeck
14.3.9 Sun Pharma
14.3.10 Wockhardt
14.3.11 UCB
14.3.12 Bausch Health
14.3.13 Acadia
